Makhteshim gets FDA OK for lycopene

Generic agrochemical producer Makhteshim Agan Ltd. said Tuesday its LycoRed Natural Products Ltd. subsidiary received FDA approval to use its lycopene products as a food coloring.

By AVI KRAWITZ
December 28, 2005 07:42

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Generic agrochemical producer Makhteshim Agan Ltd. said Tuesday its LycoRed Natural Products Ltd. subsidiary received FDA approval to use its lycopene products as a food coloring. The approval allows LycoRed to sell lycopene, which is produced from a special variety of tomato, as a natural food coloring product in the American food industry. The approval was granted after five years of testing by the FDA. The natural food coloring market is estimated to be valued at $250 million, with market share of red coloring at around $30m. - $40m.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS